Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir + PegIFN + RBV in Treatment-Naïve HCV
NCT01846832Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2013
- Primary completion
- Aug 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 3 trial of simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Started Sep 2013; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01846832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01846832.